InnoCare ICP-488 Hits Phase 3 Psoriasis Endpoint
Decision brief
Answer first · skim in under a minute
InnoCare said July 27, 2026 that fadeucravacitinib (ICP-488) met the Phase III psoriasis primary endpoint in China; PASI figures still pending.
InnoCare ICP-488 fadeucravacitinib Phase 3 psoriasis data met the primary endpoint in a China registrational trial, the company said on July 27, 2026. The oral TYK2 allosteric inhibitor also hit multiple secondary endpoints, with detailed PASI and safety tables reserved for a later congress or journal.
Contents10 sections
Key Takeaways
- Fadeucravacitinib (ICP-488) met its Phase III primary endpoint in moderate-to-severe plaque psoriasis.
- Multiple secondary endpoints were also met, per InnoCare's July 27, 2026 release.
- No new safety signals were identified versus prior studies; numeric rates were not disclosed.
- InnoCare plans to finish long-term follow-up then advance regulatory filing in China.
ICP-488 Phase III at a glance
| Field | Detail |
|---|---|
| Candidate | Fadeucravacitinib (ICP-488) |
| Sponsor | InnoCare Pharma (HKEX: 09969; SSE: 688428) |
| Class | Oral selective TYK2 allosteric inhibitor (JH2) |
| Trial | Registrational Phase III, randomized, double-blind, placebo-controlled |
| Population | Adults with moderate-to-severe plaque psoriasis (China) |
| Registry reference | NCT06842199 (Phase III ICP-488 psoriasis) |
| Announcement | Primary endpoint met — July 27, 2026 |
What did InnoCare report?
InnoCare Pharma said its novel TYK2 inhibitor fadeucravacitinib (ICP-488) met the primary endpoint with statistical significance and clinically meaningful improvement in a multicenter registrational Phase III study in moderate-to-severe plaque psoriasis. Multiple secondary endpoints were also met. Detailed efficacy and safety data were not included in the wire and are promised for scientific congresses or peer-reviewed publication.
Source: InnoCare's July 27 GlobeNewswire Phase III psoriasis release.
What does the registry say about design and endpoints?
ClinicalTrials.gov lists NCT06842199 as a multicenter, randomized, double-blind, placebo-controlled Phase III study of oral ICP-488 in Chinese adults with moderate-to-severe plaque psoriasis, with estimated enrollment of 383. Primary outcomes include sPGA 0/1 with at least a 2-point improvement at week 16 and PASI 75 at week 16.
Source: ClinicalTrials.gov record NCT06842199 for ICP-488.
The July 27 readout confirms a positive primary analysis but does not state which co-primary hierarchy was tested first or the absolute PASI 75 / sPGA response rates. Until those numbers appear, magnitude versus approved oral TYK2 or injectable IL-23/IL-17 agents cannot be ranked from public data.
Why does an oral TYK2 matter in China psoriasis care?
InnoCare described fadeucravacitinib as an oral, potent, selective TYK2 allosteric inhibitor that binds the JH2 domain and blocks IL-23, IL-12, type 1 IFN, and related cytokine signaling. The company cited high demand for novel oral options versus existing therapies and said other autoimmune indications under development include cutaneous lupus erythematosus and Sjögren's syndrome.
Earlier regulatory context includes NMPA clearance of Phase II CLE and Sjögren programs for ICP-488, documented in prior InnoCare wires such as the May 2026 Sjögren's Phase II IND GlobeNewswire notice.
- Oral once-daily class competitor set includes other TYK2 agents globally
- China prevalence cited by InnoCare at about 8.66 million people with psoriasis
- Filing planned after long-term safety follow-up completes
- No PASI/sPGA percentages in the top-line wire
What should regulators and competitors watch?
Key watch items are the full week-16 PASI 75/90 and sPGA tables, infection and lab-shift rates versus placebo, and whether dose selection matches Phase II 6 mg and 9 mg QD experience previously discussed by the company. A China NDA clock starts only after the company completes follow-up and submits; the wire does not give a filing date.
For APAC pipeline desks, the dual TYK2 franchise (ICP-488 in psoriasis plus soficitinib/ICP-332 in atopic dermatitis) is the broader InnoCare dermatology signal. Each asset still needs published Phase III numbers before formulary or partnering models can be stress-tested.
What remains unproven?
Absolute response rates, durability beyond week 16, head-to-head comparisons with deucravacitinib-class or biologic standards, and long-term safety in Chinese adults are not yet public. Commercialization is not assured until regulators review the full dossier.
Related NovaPharma coverage
- TGA expands SPEVIGO for adolescent GPP care
- NMPA Clears Kelun-Harbour Asthma Bispecific IND
- NMPA Approves Ciprocopan for PNH in China
Frequently Asked Questions
Did ICP-488 meet its Phase III psoriasis primary endpoint?
Yes. InnoCare said on July 27, 2026 that fadeucravacitinib (ICP-488) met the primary endpoint with statistical significance and clinically meaningful improvement in a China registrational Phase III plaque psoriasis study, and that multiple secondary endpoints were also met.
What endpoints does NCT06842199 list?
The ClinicalTrials.gov record lists week-16 co-primary style outcomes including sPGA 0/1 with ≥2-point improvement and PASI 75 response, in a randomized, double-blind, placebo-controlled Phase III design in Chinese adults.
When will numeric PASI data be available?
InnoCare said detailed efficacy and safety data will be presented at upcoming international congresses and/or published in a peer-reviewed journal. The July 27 wire did not include PASI or sPGA percentages.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for fadeucravacitinib.
Unlock full calendar →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
